

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

CAPRARO ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2004/013179

FILED: 19 NOVEMBER 2004

U.S. APPLICATION NO: 10/579,876

35 USC §371 DATE: 02 FEBRUARY 2007

FOR: 1H-IMIDAZO(4,5-C)QUINOLINE DERIVATIVES IN THE  
TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

**MS: Amendment**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed May 18, 2006. Since Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, no fees are believed to be required under 37 C.F.R. §1.97(b)(3). If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7898

  
Lydia T. McNally  
Attorney for Applicants  
Reg. No. 36,214

Date: June 15, 2007

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
33511-US-PCT  
APPLICATION NO.  
10/579,876  
APPLICANT  
CAPRARO ET AL.  
FILING DATE  
FEBRUARY 2, 2007

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Cantley et al., "New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/Akt pathway. Proceeding National Academic USA; 96:4240-4245
	AS	Vazquez et al., "The PTEN suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochimica et Biochimica et Biophysica Acta; 1470:M21-M35 (2000)
	AT	Simpson et al., "PTEN: Life as a tumor suppressor" Experimental Cell Research; 264:29-41 (2001)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
33511-US-PCT  
APPLICATION NO.  
10/579,876  
APPLICANT  
CAPRARO ET AL.  
FILING DATE  
FEBRUARY 2, 2007

Group

EXAMINER  
INITIAL

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	Li et al., "PTEN, "A putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancers; Vol. 275:1943-1947 (1997)
DB	Steck et al., "Identification of a candidate tumour suppressor gene MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genetics; Vol. 15:356-362 (1997)
DC	Nagase et al., "Deletion mapping on chromosome 10q25-q26 in human endometrial cancer, British Journal of Cancer; Vol. 74:1979-1983 (1996)
DD	Peiffer et al., "Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers," Cancer Research; Vol. 55:1922-1926 (1995)
DE	Gray et al., "Loss of the chromosomal region 10q23-25 in prostate cancer," Cancer Research, Vol. 55(21):4800-3 (1995)
DF	Ittmann M., "Allelic loss on chromosome 10 in prostate Adenocarcinoma Cancer Research; Vol. 56:2143-2147 (1996)
DG	Perren et al., "Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast," Am J Pathol, Vol. 155(4):1253-1260 (1999)
DH	Roberston et al., "the chromosome 10 monosomy common in human melanomas results from loss of two separate tumor suppressor loci, Cancer Res., Vol. 59(15):3596-3601 (1999)
DI	Cairns et al., "Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene; Vol. 16:3215-3218 (1998)
DJ	Gronback et al., "Alterations of the MMAC1/PTEN gene in lymphoid malignancies, Blood, Vol. 91:4388-4390 (1998)
DK	Kim et al., "Alterations of PTEN/MMAC1, a candidate tumour suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines, Oncogene, Vol. 16:89-93 (1998)
DL	Haas-Kogan et al., "Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC1. Current Biology; Vol. 8:195-1198
DM	Whang et al., "Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression, Proceeding National Academic Science USA; Vol. 95:5246-5250 (1998)
DN	Wu et al., "The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proceeding National Academic Science USA; Vol. 95:15587-15591 (1998)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
33511-US-PCT  
APPLICATION NO.  
10/579,876  
APPLICANT  
CAPRARO ET AL.  
FILING DATE  
FEBRUARY 2, 2007

Group

EXAMINER  
INITIAL

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	Yi-Hong Zhou et al., Clinical Cancer Research, Vol. 9:3369-3375 (2003)
	DB	Pullen et al., Sci, Vol. 279:707-710 (1998)
	DC	Santoro et al., Ann. N.Y. Acad. Sci., Vol. 963:116-121 (2002)
	DD	
	DE	
	DF	
	DG	
	DH	
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.